Search research articles
Contact Us
Filters
Showing results (61-70 of 81) with videos related to
Page
of 9
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 28, 2022
Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR- Trial
Monika Graeser, Oleg Gluz, Claudia Biehl, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 30, 2021
Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial
Yen-Shen Lu, Seock-Ah Im, Marco Colleoni, et al.
The Lancet. Oncology
|
May 3, 2025
Chemotherapy-free neoadjuvant pembrolizumab combined with trastuzumab and pertuzumab in HER2-enriched early breast cancer (WSG-KEYRICHED-1): a single-arm, phase 2 trial
Sherko Kuemmel, Monika Graeser, Peter Schmid, et al.
Annals of Surgical Oncology
|
November 10, 2023
Minimally Invasive Breast Biopsy After Neoadjuvant Systemic Treatment to Identify Breast Cancer Patients with Residual Disease for Extended Neoadjuvant Treatment: A New Concept
André Pfob, Lie Cai, Andreas Schneeweiss, et al.
The Lancet. Oncology
|
August 19, 2014
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response
Evandro de Azambuja, Andrew P Holmes, Martine Piccart-Gebhart, et al.
The Lancet. Oncology
|
May 29, 2018
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
Debu Tripathy, Seock-Ah Im, Marco Colleoni, et al.
The Lancet. Oncology
|
August 7, 2025
[<sup>68</sup>Ga]Ga-FAPI-46 PET accuracy for cancer imaging with histopathology validation: a single-centre, single-arm, interventional, phase 2 trial
Kim M Pabst, Manuel M Weber, Christina Laschinsky, et al.
JAMA Oncology
|
August 30, 2019
Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial
Peter Schmid, Matthias Zaiss, Catherine Harper-Wynne, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 22, 2020
Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial
Suzette Delaloge, Martine Piccart, Emiel Rutgers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 7, 2021
A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer
Sherko Kuemmel, Mario Campone, Delphine Loirat, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 81) with videos related to
Sort By:
Page
of 9
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 28, 2022
Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR- Trial
Monika Graeser, Oleg Gluz, Claudia Biehl, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 30, 2021
Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial
Yen-Shen Lu, Seock-Ah Im, Marco Colleoni, et al.
The Lancet. Oncology
|
May 3, 2025
Chemotherapy-free neoadjuvant pembrolizumab combined with trastuzumab and pertuzumab in HER2-enriched early breast cancer (WSG-KEYRICHED-1): a single-arm, phase 2 trial
Sherko Kuemmel, Monika Graeser, Peter Schmid, et al.
Annals of Surgical Oncology
|
November 10, 2023
Minimally Invasive Breast Biopsy After Neoadjuvant Systemic Treatment to Identify Breast Cancer Patients with Residual Disease for Extended Neoadjuvant Treatment: A New Concept
André Pfob, Lie Cai, Andreas Schneeweiss, et al.
The Lancet. Oncology
|
August 19, 2014
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response
Evandro de Azambuja, Andrew P Holmes, Martine Piccart-Gebhart, et al.
The Lancet. Oncology
|
May 29, 2018
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
Debu Tripathy, Seock-Ah Im, Marco Colleoni, et al.
The Lancet. Oncology
|
August 7, 2025
[<sup>68</sup>Ga]Ga-FAPI-46 PET accuracy for cancer imaging with histopathology validation: a single-centre, single-arm, interventional, phase 2 trial
Kim M Pabst, Manuel M Weber, Christina Laschinsky, et al.
JAMA Oncology
|
August 30, 2019
Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial
Peter Schmid, Matthias Zaiss, Catherine Harper-Wynne, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 22, 2020
Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial
Suzette Delaloge, Martine Piccart, Emiel Rutgers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 7, 2021
A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer
Sherko Kuemmel, Mario Campone, Delphine Loirat, et al.
Page
of 9